← Insulin × glycemic control

SynthesisBMJ open2015

An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.

Jie Sun et al.PubMed ↗Full text ↗Publisher ↗

  • Combination of statins and metforminno clear effectLower c reactive protein, lower triglyceride, lower total cholesterol.Nothing cleared the noise.
  • Combined therapyno clear effectNo clear effect on fasting insulin, no clear effect on homeostasis model assessment of insulin resistance, no clear effect on total testosterone.Nothing cleared the noise.

What the trial testedas reported · 2015

Range includes no effect

No clear effect on fasting insulin

−0.92−2.07 to +0.24

combined therapy vs metformin alone

As reported

difference −0.92, 95% CI −2.07 to 0.24

Range includes no effect

No clear effect on homeostasis model assessment of insulin resistance

−1.15−3.36 to +1.06

combined therapy vs metformin alone

As reported

difference −1.15, 95% CI −3.36 to 1.06

Range includes no effect

No clear effect on total testosterone

−1.12−2.29 to +0.05

combined therapy vs metformin alone

As reported

difference −1.12, 95% CI −2.29 to 0.05

Not counted

Probably lowered c reactive protein

−0.91−1.81 to −0.02

combination of statins and metformin vs metformin alone

As reported

difference −0.91, 95% CI −1.81 to −0.02

+3 more in the walkthrough ↓

Who was studied, and how

people with dyslipidemia, in this paper

The trial randomly assignedassigned by chance

combination of statins and metformin
metformin alone

Probably lowered c reactive protein−0.91

Probably lowered triglyceride−1.37

Probably lowered total cholesterol−1.28

randomised

The trial randomly assignedassigned by chance

combined therapy
metformin alone

No clear effect on fasting insulin−0.92

No clear effect on homeostasis model assessment of insulin resistance−1.15

No clear effect on total testosterone−1.12

randomised

the abstract, start to end

… (standardised mean difference (SMD) -0.91; 95% CI -1.81 to -0.02; p=0.046), triglyceride (SMD -1.37; 95% CI -2.46 to -0.28; p=0.014), total cholesterol (SMD -1.28; 95% CI -1.59 to -0.97; p=0.000) and low-density lipoprotein (LDL) cholesterol (SMD -0.74; 95% CI -1.03 to -0.44; …

… fails to reduce fasting insulin (SMD -0.92; 95% CI -2.07 to 0.24; p=0.120), homeostasis model assessment of insulin resistance (SMD -1.15; 95% CI -3.36 to 1.06; p=0.309) and total testosterone (SMD -1.12; 95% CI -2.29 to 0.05; …

← favours treatmentfavours comparator →
could be chance
C reactive proteincombination of statins and metformin vs metformin alone
−0.91−1.81 to −0.02
Triglyceridecombination of statins and metformin vs metformin alone
−1.37−2.46 to −0.28
Total cholesterolcombination of statins and metformin vs metformin alone
−1.28−1.59 to −0.97
Low-density lipoprotein (LDL) cholesterolcombination of statins and metformin vs metformin alone
−0.74−1.03 to −0.44
Fasting insulincombined therapy vs metformin alone
−0.92−2.07 to 0.24
Homeostasis model assessment of insulin resistancecombined therapy vs metformin alone
−1.15−3.36 to 1.06
Total testosteronecombined therapy vs metformin alone
−1.12−2.29 to 0.05
StatinsMetforminInsulinGlycemic controlLipidsInflammation & biomarkers
1 / 5

16 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 25818277